Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction

NCT ID: NCT01658514

Last Updated: 2015-12-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 39 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2014-06-30

Brief Summary

This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction, or severe kidney dysfunction. The safety and tolerability of Met DR was also examined. In addition, this study compared the behavior of a single dose of Met DR with that of extended-release metformin (Met XR) and placebo in subjects with the varying levels of kidney function described above.

Conditions

Renal Insufficiency

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Met DR

One dose of 1000 mg metformin delayed-release

Group Type: EXPERIMENTAL

Met DR

Intervention Type: DRUG

metformin delayed-release tablets

Met XR

One dose of 1000 mg metformin extended-release

Group Type: ACTIVE_COMPARATOR

Met XR

Intervention Type: DRUG

metformin extended-release tablets

Placebo

One dose of Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

Met DR

metformin delayed-release tablets

Intervention Type: DRUG

Met XR

metformin extended-release tablets

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. 18 to 80 (inclusive) years old at Visit 1 (Screening)

2. Male, or female and met all of the following criteria:

• Not breastfeeding
• Negative pregnancy test result at Visit 1 (Screening) (not applicable to postmenopausal or surgically sterile females)
• Surgically sterile, postmenopausal, or if of childbearing potential, practiced and was willing to continue to practice appropriate birth control during the entire duration of the study
• Body weight of ≥45 kg

3. Body mass index (BMI) of 18.0 to 40.0 kg/m² (inclusive) at Visit 1 (Screening)

4. Had type 2 diabetes mellitus and an HbA1c ≤10.0%

5. Had a physical examination with no clinically significant abnormalities as judged by the investigator

6. Estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation

7. Ability to understand and willingness to adhere to protocol requirements

Exclusion Criteria

1. Had End Stage Renal Disease requiring dialysis or severe renal dysfunction with eGFR <15 mL/min/1.73 m²

2. Was on dialysis or had been on dialysis within 12 months of Visit 1 (Screening)

3. Had received or planned to receive any iodinated contrast dye within 1 week prior to Visit 1 (Screening) or after study medication administration

4. Was taking or had taken within 1 week of Visit 1 cationic drugs that are eliminated by renal tubular secretion (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin)

5. Had a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:

• Hepatic disease
• Gastrointestinal disease
• Endocrine disorder (type 2 diabetes mellitus was allowed)
• Cardiovascular disease
• Central nervous system diseases
• Psychiatric or neurological disorders
• Organ transplantation
• Chronic or acute infection
• Orthostatic hypotension, fainting spells or blackouts
• Allergy or hypersensitivity

6. Had any chronic disease requiring medication that had been adjusted in the past 14 days (subjects could take acute intermittent over-the-counter medications such as Tylenol, if needed)

7. Had major surgery of any kind within 6 months of Visit 1 (Screening)

8. Had a clinically significant finding of an electrocardiogram (ECG) as assessed by the investigator at Visit 1 (Screening)

9. Had clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities, other than those related to diabetes or renal disease and other stable diseases, judged by the investigator to be clinically significant at Visit 1 (Screening)

10. Had a hemoglobin result <8 g/dL or a level indicating severe anemia of renal origin

11. Had a physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study

12. Had received Byetta® or short-acting insulin within 3 days of Visit 1 (Screening)

13. Had received metformin within 4 weeks of Visit 1 (Screening)

14. Had any drug treatment that affects gastrointestinal motility or gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid, within 2 days of Visit 2

15. Abused drugs or alcohol or had a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures

16. Smoked more than 10 cigarettes, 3 cigars, or 3 pipes per day

17. Had donated blood within 2 months of Visit 1 (Screening) or was planning to donate blood during the study

18. Had received any investigational drug within one month (or seven half-lives of the investigational drug, whichever was greater) of Visit 1 (Screening)

19. Had known allergies or hypersensitivity to any component of study treatment

20. Was employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Elcelyx Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

George Canas, MD

Role: PRINCIPAL_INVESTIGATOR

Prism Research

Kenneth Lasseter, MD

Role: PRINCIPAL_INVESTIGATOR

Clinical Pharmacology of Miami, Inc

Alexander White, MD

Role: PRINCIPAL_INVESTIGATOR

Progressive Medical Research

Harold Bays, MD

Role: PRINCIPAL_INVESTIGATOR

Louisville Metabolic and Atherosclerosis Research Center

Craig Curtis, MD

Role: PRINCIPAL_INVESTIGATOR

Compass Research

Prabir Roy-Chaudhury

Role: PRINCIPAL_INVESTIGATOR

Cincinnati Veterans Affairs Medical Center Department of Internal Medicine

Sunder Mudaliar

Role: PRINCIPAL_INVESTIGATOR

San Diego Veterans Healthcare System

Nelson Kopyt

Role: PRINCIPAL_INVESTIGATOR

Northeast Clinical Research Center

Countries

United States

References

Bakris GL, Mudaliar, S, Kim T, Burns C, Skare S, Baron A, Fineman M. Effects of New Metformin Formulation in Stage 3 and 4 CKD: A Pilot Study. J Am Soc Nephrol. 2014; 25:549A.

Reference Type: RESULT

DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. Epub 2015 Oct 9.

Reference Type: RESULT

PMID: 26773926 (View on PubMed)

Other Identifiers

LCRM101

Identifier Type: -

Identifier Source: org_study_id